These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29739463)

  • 81. Deliberation on Childhood Vaccination in Canada: Public Input on Ethical Trade-Offs in Vaccination Policy.
    O'Doherty KC; Crann S; Bucci LM; Burgess MM; Chauhan A; Goldenberg MJ; McMurtry CM; White J; Willison DJ
    AJOB Empir Bioeth; 2021; 12(4):253-265. PubMed ID: 34328070
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Public Deliberation Process on Patient Perspectives on Health Information Sharing: Evaluative Descriptive Study.
    Raj M; Ryan K; Nong P; Calhoun K; Trinidad MG; De Vries R; Creary M; Spector-Bagdady K; Kardia SLR; Platt J
    JMIR Cancer; 2022 Sep; 8(3):e37793. PubMed ID: 36112409
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Difficult decisions in times of constraint: criteria based resource allocation in the Vancouver Coastal Health Authority.
    Mitton C; Dionne F; Damji R; Campbell D; Bryan S
    BMC Health Serv Res; 2011 Jul; 11():169. PubMed ID: 21756357
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Sharing linked data sets for research: results from a deliberative public engagement event in British Columbia, Canada.
    Teng J; Bentley C; Burgess MM; O'Doherty KC; McGrail KM
    Int J Popul Data Sci; 2019 May; 4(1):1103. PubMed ID: 34095532
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):e128-53. PubMed ID: 19305760
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):54-63. PubMed ID: 19305768
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.
    Morgan S; Evans RG; Hanley GE; Caetano PA; Black C
    Healthc Policy; 2006 Nov; 2(2):115-27. PubMed ID: 19305708
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency.
    Gandjour A
    BMC Health Serv Res; 2020 Mar; 20(1):240. PubMed ID: 32293433
    [TBL] [Abstract][Full Text] [Related]  

  • 90. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.
    Ubel PA; Berry SR; Nadler E; Bell CM; Kozminski MA; Palmer JA; Evans WK; Strevel EL; Neumann PJ
    Health Aff (Millwood); 2012 Apr; 31(4):709-17. PubMed ID: 22492887
    [TBL] [Abstract][Full Text] [Related]  

  • 91. 6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.
    Browman GP; Manns B; Hagen N; Chambers CR; Simon A; Sinclair S
    J Oncol Pract; 2008 Jan; 4(1):2-7. PubMed ID: 20859436
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
    Niraula S
    Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Community engagement for big epidemiology: deliberative democracy as a tool.
    McWhirter RE; Critchley CR; Nicol D; Chalmers D; Whitton T; Otlowski M; Burgess MM; Dickinson JL
    J Pers Med; 2014 Nov; 4(4):459-74. PubMed ID: 25563457
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The efficiency-equity trade-off, self-interest, and moral principles in health and safety valuation.
    Arroyos-Calvera D; Covey J; Loomes G; McDonald R
    Soc Sci Med; 2019 Oct; 238():112477. PubMed ID: 31434030
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The Importance of Economic Trade-offs in Cancer Drug Pricing.
    Fonseca R; Peneva D; Clancy Z; Abouzaid S; Jena AB
    Mayo Clin Proc; 2018 Aug; 93(8):976-979. PubMed ID: 29945732
    [No Abstract]   [Full Text] [Related]  

  • 96. Using deliberative methods to establish a sufficient state of capability well-being for use in decision-making in the contexts of public health and social care.
    Kinghorn P
    Soc Sci Med; 2019 Nov; 240():112546. PubMed ID: 31563761
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Establishing Heat Alert Thresholds for the Varied Climatic Regions of British Columbia, Canada.
    McLean KE; Stranberg R; MacDonald M; Richardson GRA; Kosatsky T; Henderson SB
    Int J Environ Res Public Health; 2018 Sep; 15(9):. PubMed ID: 30235814
    [TBL] [Abstract][Full Text] [Related]  

  • 98. How deliberative designs empower citizens' voices: A case study on Ghana's deliberative poll on agriculture and the environment.
    Chen K
    Public Underst Sci; 2021 Feb; 30(2):179-195. PubMed ID: 33103601
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Appropriateness for Total Joint Replacement: Perspectives of Decision-Makers.
    Clavel N; De Coster C; Pomey MP; Sanmartin C; Bohm É; Dunbar MJ; Frank CY; Hawker G; Noseworthy T
    Healthc Policy; 2016 Feb; 11(3):80-92. PubMed ID: 27027795
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Application of a policy framework for the public funding of drugs for rare diseases.
    Winquist E; Coyle D; Clarke JT; Evans GA; Seager C; Chan W; Martin J
    J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S774-9. PubMed ID: 25029973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.